Iovance Stock Been Hammered: A Buying Opportunity or Lure for Risky Bets
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Explore the debate of cash back vs. points to determine which rewards suit your spending habits best. Make informed choices for your finances.
26,869 articlesIovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
In a volatile market, CVS Health leads a retirement-focused view of the magic formula, topping Qualcomm and Valero as...
As UnitedHealth gears up for its July 16 results, traders focus on pricing power and rising cash flow as the main rea...
Warner Bros. Discovery says it is reviewing Paramount's new bid while maintaining its Netflix-backed proposal for War...
ZIM shares hover near $27.54, well under Hapag-Lloyd’s $35 cash proposal. The discount reflects regulatory risk aroun...
For the first time in decades, Berkshire Hathaway held its annual meeting without Warren Buffett. Executives laid out...
Bond traders pulled back on AI-linked notes after Amazon revealed a new $25 billion borrowing plan, triggering a broa...
Nuclear power is staging a comeback, and it could reshape how you invest in utilities. This guide breaks down why the...
A quarterly data snapshot reveals moves by the wealthiest fund managers. This piece dives into why these billionaire ...
A global fan moment is a chance to rethink entertainment budgeting. As miley cyrus teases epic comeback, learn practi...
JPMorgan Chase CEO Jamie Dimon warns that markets may be riding an exuberant wave around AI and Big Tech, signaling ...
When a founder makes a bold move after a price drop, investors sit up and take notice. This article unpacks what a pu...